Headquartered in South San Francisco, Surrozen focuses on developing drugs by leveraging insights into the Wnt signaling pathway. Source: BioSpace

Here are five possible acquisition targets to keep an eye on. Source: BioSpace

Narasimhan takes over the role of CEO in February as current CEO Joe Jimenez retires. Source: BioSpace

Entresto, introduced in 2015, got off to a slow start but brought in $507 million in revenue last year. Source: BioSpace

The latest funding round gives XtalPi $20M in the bank, which the company said makes it "one of the top-funded AI-powered biotechs." Source: BioSpace

The company expects the new facility will include commercial manufacturing capabilities in 18 to 24 months. Source: BioSpace

The companies will collaborate on research to study a previously unrecognized role for peripheral immune cells in the pathology of central nervous system disorders. Source: BioSpace

The year is already off to a good start with mergers and acquisitions in the biopharma industry. Source: BioSpace

Fortis Therapeutics is focused on immuno-oncology, specifically on developing an ADC for multiple myeloma and late-stage prostate cancer, including both the adenocarcinoma and neuroendocrine types. Source: BioSpace

Hannestad will be responsible for Alkahest's clinical programs in Alzheimer's and Parkinson's Disease. Source: BioSpace